Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.58 |
| ▸ | SLC1A3 | P43003 | 4/20 | 0.45 |
| ▸ | SLC1A2 | P43004 | 4/20 | 0.45 |
| ▸ | ANPEP | P15144 | 7/20 | 0.42 |
| ▸ | RNPEP | Q9H4A4 | 4/20 | 0.42 |
| ▸ | DNPEP | Q9ULA0 | 2/20 | 0.42 |
| ▸ | ELANE | P08246 | 1/20 | 0.42 |
| ▸ | LARS1 | Q9P2J5 | 1/20 | 0.40 |
| ▸ | LAP3 | P28838 | 2/20 | 0.39 |
| ▸ | ERAP1 | Q9NZ08 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | SLC1A1 | P43005 | 3/20 | 0.38 |
| ▸ | AAK1 | Q2M2I8 | 1/20 | 0.38 |
| ▸ | CACNB3 | P54284 | 1/20 | 0.35 |
| ▸ | CACNA2D1 | P54289 | 1/20 | 0.35 |
| ▸ | CACNA1C | Q13936 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13895431 | 1.00 | SLC7A5 (0.58) | SLC7A5SLC1A3SLC1A2ANPEPRNPEP | |
| SCHEMBL12214830 | 1.00 | SLC7A5 (0.58) | SLC7A5SLC1A3SLC1A2ANPEPRNPEP | |
| SCHEMBL28866572 | 0.81 | SLC7A5 (0.54) | SLC7A5SLC1A3SLC1A2ANPEPRNPEP | |
| SCHEMBL13499200 | 0.81 | SLC7A5 (0.54) | SLC7A5SLC1A3SLC1A2ANPEPRNPEP | |
| SCHEMBL23966934 | 0.80 | SLC7A5 (0.58) | SLC7A5SLC1A3SLC1A2ANPEPRNPEP | |
| SCHEMBL8823909 | 0.80 | SLC7A5 (0.58) | SLC7A5SLC1A3SLC1A2ANPEPRNPEP | |
| SCHEMBL28095787 | 0.80 | SLC7A5 (0.58) | SLC7A5SLC1A3SLC1A2ANPEPRNPEP | |
| SCHEMBL24929107 | 0.80 | SLC1A2 (0.37) | SLC7A5SLC1A3SLC1A2ALDH1A1SLC1A1 | |
| SCHEMBL10297430 | 0.78 | SLC7A5 (0.56) | SLC7A5SLC1A3SLC1A2ANPEPRNPEP | |
| SCHEMBL10021630 | 0.78 | SLC7A5 (0.56) | SLC7A5SLC1A3SLC1A2ANPEPRNPEP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-5194415-A | — | — | None | — | — | JP | disclosed |
| US-11406642-B2 | DNP and DNP prodrug treatment of neuromuscular, neurodegenerative, autoimmune, developmental, traumatic brain injury, concussion, dry eye disease, hearing loss and/or metabolic diseases | MITOCHON PHARMACEUTICALS, INC. (US) | 2022-08-09 | — | — | US | disclosed |
| US-20210277050-A1 | OPHTHALMIC COMPOSITIONS AND METHODS FOR THE TREATMENT OF EYE DISORDERS | CELLIX BIO PRIVATE LIMITED (IN) | 2021-09-09 | — | — | US | disclosed |
| US-20200093831-A1 | DNP and DNP Prodrug Treatment of Neuromuscular, Neurodegenerative, Autoimmune, Developmental, Traumatic Brain Injury, Concussion, Dry Eye Disease, Hearing Loss and/or Metabolic Diseases | MITOCHON PHARMACEUTICALS, INC. (US) | 2020-03-26 | — | — | US | disclosed |
| WO-2019173602-A1 | 4'-HALOGEN CONTAINING NUCLEOTIDE AND NUCLEOSIDE THERAPEUTIC COMPOSITIONS AND USES RELATED THERETO | EMORY UNIVERSITY (US) | 2019-09-12 | — | — | WO | disclosed |
| US-20170252347-A1 | DNP and DNP Prodrug Treatment of Neuromuscular, Neurodegenerative, Autoimmune, Developmental, Traumatic Brain Injury, Concussion, Dry Eye Disease, Hearing Loss and/or Metabolic Diseases | MITOCHON PHARMACEUTICALS, INC. | 2017-09-07 | — | — | US | disclosed |
| US-20160193347-A1 | MULTI-TARGETED UBENIMEX PRODRUG DERIVATIVE AND PREPARATION METHOD AND USE THEREOF | WEIFANG BOCHUANG INTERNATIONAL ACADEMY OF BIOTECHNOLOGY AND MEDICINE (CN) | 2016-07-07 | — | — | US | disclosed |
| US-20150140605-A1 | ONE STEP N-TERMINAL TAGGING OF PROTEINS | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA | 2015-05-21 | — | — | US | disclosed |
| WO-2015006100-A1 | ARYL AMIDE KINASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2015-01-15 | — | — | WO | disclosed |
| US-8859538-B2 | Uses of substituted imidazoheterocycles | CARA THERAPEUTICS, INC. (US) | 2014-10-14 | — | — | US | disclosed |
| US-8093427-B2 | Construction and screening of solution-phase derived library of fenbufen and ethacrynic acid | NATIONAL TSING HUA UNIVERSITY (TW) | 2012-01-10 | — | — | US | disclosed |
| US-20110306668-A1 | CONSTRUCTION AND SCREENING OF SOLUTION-PHASE DERIVED LIBRARY OF FENBUFEN AND ETHACRYNIC ACID | NATIONAL TSING HUA UNIVERSITY (TW) | 2011-12-15 | — | — | US | disclosed |
| US-20110034443-A1 | USES OF SUBSTITUTED IMIDAZOHETEROCYCLES | CARA THERAPEUTICS, INC. (US) | 2011-02-10 | — | — | US | disclosed |
| US-20070218010-A1 | Contrast Agents for Magnetic Resonance Imaging | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) | 2007-09-20 | — | — | US | disclosed |
| US-5643908-A | ANGIOGENESIS INHIBITOR, ANTITUMOR | SANKYO COMPANY, LIMITED (JP) | 1997-07-01 | — | — | US | disclosed |
| EP-0621270-A1 | COLLAGENASE INHIBITOR | SANKYO COMPANY LIMITED (JP) | 1994-10-26 | — | — | EP | disclosed |
| JP-H05194415-A | COLLAGENASE INHIBITOR | SANKYO CO LTD | 1993-08-03 | — | — | JP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200093831-A1 | DNP and DNP Prodrug Treatment of Neuromuscular, Neurodegenerative, Autoimmune, Developmental, Traumatic Brain Injury, Concussion, Dry Eye Disease, Hearing Loss and/or Metabolic Diseases | SMN1; SMN2, MYLK2, WFS1 | SLC7A5 2485/4885SLC1A3 816/4885SLC1A2 925/4885 |
| US-20150140605-A1 | ONE STEP N-TERMINAL TAGGING OF PROTEINS | TRMT1, RNGTT, NSUN3 | SLC7A5 1990/4885SLC1A3 2295/4885SLC1A2 3159/4885 |
| US-20070218010-A1 | Contrast Agents for Magnetic Resonance Imaging | MAG, SLC40A1, FABP7 | SLC7A5 780/4885SLC1A3 283/4885SLC1A2 251/4885 |
| US-20160193347-A1 | MULTI-TARGETED UBENIMEX PRODRUG DERIVATIVE AND PREPARATION METHOD AND USE THEREOF | ANPEP, DNPEP, ENPEP | SLC7A5 963/4885SLC1A3 275/4885SLC1A2 1789/4885 |
| US-20110034443-A1 | USES OF SUBSTITUTED IMIDAZOHETEROCYCLES | CNR2, CNR1, TRPV1 | SLC7A5 3599/4885SLC1A3 1563/4885SLC1A2 1746/4885 |
| US-20170252347-A1 | DNP and DNP Prodrug Treatment of Neuromuscular, Neurodegenerative, Autoimmune, Developmental, Traumatic Brain Injury, Concussion, Dry Eye Disease, Hearing Loss and/or Metabolic Diseases | SMN1; SMN2, MYLK2, WFS1 | SLC7A5 2485/4885SLC1A3 816/4885SLC1A2 925/4885 |
| US-20210277050-A1 | OPHTHALMIC COMPOSITIONS AND METHODS FOR THE TREATMENT OF EYE DISORDERS | F5, OR10J3, SHBG | SLC7A5 2176/4885SLC1A3 3136/4885SLC1A2 2139/4885 |
| US-20110306668-A1 | CONSTRUCTION AND SCREENING OF SOLUTION-PHASE DERIVED LIBRARY OF FENBUFEN AND ETHACRYNIC ACID | CYP4F2, ACR, CYP4F3 | SLC7A5 2267/4885SLC1A3 1849/4885SLC1A2 2628/4885 |
| US-11406642-B2 | DNP and DNP prodrug treatment of neuromuscular, neurodegenerative, autoimmune, developmental, traumatic brain injury, concussion, dry eye disease, hearing loss and/or metabolic diseases | SMN1; SMN2, MYLK2, WFS1 | SLC7A5 2485/4885SLC1A3 816/4885SLC1A2 925/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.